Diagnosis and multidisciplinary treatment of sporadical desmoid tumors by Mátrai, Zoltán Tamás
 1 







Zoltán Tamás Mátrai, M.D. 
 
 
Supervisor: Prof. Dr. Miklós Kásler Ph.D., D.Sc., Dr.h.c. 
 
 

















PUBLICATTIONS RELATED TO THE THESIS 
1. Mátrai Z, Tóth L, Szentirmay Z, Papp J, Langmár Z, Kásler M Multidisciplinary 
treatment of intra-thoracic desmoid tumours: case series and narrative review.  
Med Sci Monit. 2012, 18: 17-25.      IF: 1.699* 
2. Mátrai Z, Tóth L, Szentirmay Z, Papp J, Antal I, Vadász P, Bartal A, Kásler M  
Surgical challenges of chest wall and intra-thoracic desmoid tumors. Orvosi Hetilap, 
2011, 152: 3-13. 
3. Mátrai Z, Tóth L, Gulyás G, Szabó E, Szentirmay Z, Kásler M. A desmoid tumor  
associa-ted with a ruptured silicone breast implant. Plast Reconstr Surg. 
 2011, 127: 1-4.          IF: 2.635* 
4. Mátrai Z, Tóth L, Szentirmay Z, Vámos FR, Klepetko W, Vadász P, Kenessey I,  
Kásler M. Sporadic desmoid tumors of the chest: long-term follow-up of 28 
multimodally treated patients. Eur J Cardiothorac Surg. 2011, 40: 1170-1176.  
   IF: 2.293* 
5. Mátrai Z, Tóth L, Rényi Vámos F, Papp J, Gıdény M, Bartal A, Szentirmay Z, 
Kásler M Giant intra-thoracic desmoid tumour. Case report. Med. Thor. 2010, 63: 158-
166.  
6. Mátrai Z, Papp J, Polgár C, Hitre E, Köves I, Oláh E, Andi J, Kiss A, Vámosi Nagy I,  
Tóth L, Orosz Z Long-term experience with therapy of a Gardner's syndrome female, 
first presenting with extra-abdominal desmoid tumor, and review of the literature. 
Magy Seb. 2009, 62: 75-82. 
7. Mátrai Z, Péley G, Rényi Vámos F, Farkas E, Kovács T, Köves I The similarities  
between the mechanism of wound healing and tumor development--literature review 
on the occasion of a patient with colonic adenocarcinoma metastasis in a dog-bite 
wound. Orv Hetil.  2005, 146: 99-109.  
 
ΣIF = 6.6272*   
* Source: Magyar Tudományos Mővek Tárháza 
 
PUBLICATIONS NOT DIRECTLY RELATED TO THE THESIS 
1. Mátrai Z, Gulyás G, Tizedes G, Tóth L, Langmár Z, Kásler M. Bilateral juvenile 
fibroadenoma of the breast: Management with subcutaneous mastectomy and silicone 
implant placement. European Journal of Gynaecological Oncology, 2012 (accepted 
for publication) 
2. Mátrai Z, Tóth L, Sávolt Á, Tínusz A, Palla É, Bartal A, Horti I, Kásler M Breast 
care nurse. A new specialist in the multidisciplinary care of breast cancer patients. 
Magy Onkol. 2012 (accepted for publication)    
3. Bartal A, Mátrai Z, Szőcs A, Belinszkaja G, Langmár Z, Rosta A Novel oral 
anticancer drugs: a review of adverse drug reactions, interactions and patient 
adherence. Orv Hetil. 2012, 153: 66-78.  
4. Gulyás G, Mátrai Z, Kunos C, Pesthy P, Doleviczényi Z, Kásler M Modern breast 
surgery. Orv Hetil. 2012, 153: 31-38.  
5. Bartal A, Mátrai Z, Rosta A, Szőcs A Introduction of a clinical protocol for 
extravasation at the National Institute of Oncology, Budapest, Hungary. Magy Onkol. 
2011, 55: 14-20.  
6. Bartal A, Mátrai Z, Szőcs A, Liszkay G Main treatment and preventive measures for 
hand-foot syndrome, a dermatologic side effect of cancer therapy. Magy Onkol. 
2011, 55: 91-98. 
 3 
7. Langmár Z, Németh M, Kolozsvári LR, Joó JG, Mátrai Z Cancer of the vagina. Orv 
Hetil. 2011, 152: 1974-1976.  
8. Mátrai Z, Gulyás G, Tóth L, Polgár C, Bidlek M, Szabó E, Láng I, Horváth Z, 
Udvarhelyi N, Kunos C, Sávolt A, Pesthy P, Kásler M Challenges in oncologic plastic 
surgery of the breast. Magy Onkol. 2011, 55: 40-52.  
9. Mátrai Z, Gulyás G, Tóth L, Sávolt A, Kunos C, Pesthy P, Bartal A, Kásler M Role 
of nipple sparing mastectomy in modern breast surgery. Orv Hetil. 2011, 152: 1233-
1249.  
10. Mátrai Z, Tóth L, Polgár C, Láng I, Gödény M, Sinkovics I, Horváth Z, Bidlek M, 
Udvarhelyi N, Bartal A, Sávolt A, Ujhelyi M, Kásler M Sentinel lymph node biopsy 
after neoadjuvant chemotherapy in breast cancer. Magy Onkol. 2011, 55: 73-84.  
11. Mátrai Z, Gulyás G, Tóth L, Sávolt A, Kunos C, Pesthy P, Bartal A, Szabó E, Kásler 
M Special considerations in breast cancer treatment of an augmented breast. Orv Hetil. 
2011, 152: 1679-1691.  
12. Mátrai Z, Gulyás G, Tóth L, Sávolt A, Kunos C, Pesthy P, Bartal A, Kásler M The 
place of skin-sparing mastectomy in oncoplastic breast surgery. Magy Onkol. 2011, 
55: 252-267.  
13. Mátrai Z, Tóth L, Bidlek M, Szabó E, Farkas E, Sávolt A, Góbor L, Bartal A, Kásler 
M The potential role of ductoscopy in modern breast diagnostics and therapy. Orv 
Hetil. 2011, 152: 1284-1293. 
14. Mátrai Z, Tóth L, Saeki T, Sinkovics I, Gödény M, Takeuchi H, Bidlek M, Bartal A, 
Sávolt A, Dorogi B, Kásler M The potential role of SPECT/CT in the preoperative 
detection of sentinel lymph nodes in breast cancer. Orv Hetil. 2011, 152: 678-688. 
(Lajos Markusovszky Price 2011) 
15. Mátrai Z, Tóth L, Polgár C, Láng I, Gıdény M, Sinkovics I, Horváth Z, Bidlek M, 
Udvarhelyi N, Bartal A, Sávolt A;, Ujhelyi M;, Kásler M; Sentinel lymph node biopsy 
after neoadjuvant chemotherapy in breast cancer. Magy Onkol. 2011, 8: 73-84.  
16. Mátrai Z, Tóth L, Saeki T, Sinkovics I, Gıdény M, Takeuchi H, Bidlek M, Bartal A 
Sávolt A, Dorogi B, Kásler M The potential role of SPECT/CT in the preoperative 
detection of sentinel lymph nodes in breast cancer. Orv Hetil. 2011, 24: 678-688.  
17. Mátrai Z, Gulyás G, Tóth L, Sávolt A, Bidlek M, Szabó E, Pesthy P, Kunos C, Bartal 
A, Kásler M Breast conserving oncoplastic surgery in the treatment of centrally 
located malignant breast tumors. Orv Hetil. 2010, 151: 2105-2112.  
18. Mátrai Z, Langmár Z, Szabó E, Rényi-Vámos F, Bartal A, Orosz Z, Németh M, Tóth 
L Granular cell tumour of the breast: case series and review of the literature. Eur J 
Gynaecol Oncol. 2010, 31: 636-640.     IF: 0.633  
19. Mátrai Z, Liszkay G, Plotár V, Orosz Z, Székely J, Hitre E, Bartal A, Langmár Z, 
Bocs K, Rényi Vámos F, Sávolt Á, Tóth L Long-term experience with 
multidisciplinary therapy of twenty-six patients with dermatofibrosarcoma 
protuberans. Orv Hetil. 2009, 150: 1894-1902.  
20. Mátrai Z, Plotár V, Liszkay G, Fejıs Z, Vámosi A, Dubóczky Z, Rényi Vámos F, 
Vámosi Nagy I, Köves I, Bartal A, Schmidt E, Tóth L Recurrent acral lentigous 
melanoma successfully treated with Mohs' micrographic surgery. Case report and 
review of the literature. Orv Hetil. 2009, 150: 1071-1082.  
21. Góbor L, Czeyda-Pommersheim F, Mátrai Z, Köves I Rectum carcinomas treated 
with Kraske procedure in elderly patients. Magy Seb. 2007, 60: 289-292.  
22. Mátrai Z, Péley G, Kovács T, Rényi VF, Szivós E, Szabó E, Vereczkey I, Török K, 
Köves I Cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion for 
peritoneal carcinomatosis caused by recurrent inflammatory myofibroblastic sarcoma: 
a case report and review of the literature. Orv Hetil. 2006, 147: 147-158. 
 4 
23. Matrai Z, Lıvey J, Hitre E, Orosz Z, Gödény M, Péley G, Sulyok Z, Rényi Vámos F, 
Farkas E, Köves I  Histologic response after neoadjuvant therapy in rectal 
adenocarcinoma: own experience and review of the literature. Orv Hetil. 2006, 147: 
2011-2020.  
24. Török K, Péley G, Mátrai Z, Bidlek M, Szabó É, Sinkovics I, Polgár C, Farkas E, 
Orosz Z, Köves I The role of sentinel lymph node biopsy in breast cancer non-
invading-duct. Magy Seb. 2006, 59: 173-178.  
25. Farkas E, Péley G, Mátrai Z, Rényi-Vámos F, Köves I Administration of clexane 
4000 U/0.4 ml (40 mg) for preventing venous thromboembolic complications in 
patients undergoing surgery for malignant tumors. A follow-up study. Magy Seb. 
2005, 58: 197-200.  
26. Mátrai Z, Fehér I, Péley G, Rényi Vámos F, Farkas E, Sulyok Z, Kovács T, Köves I 
Experience with radiofrequency ablation in the treatment of unresectable pelvic 
recurrence of rectal cancer. Magy Seb. 2005, 58: 21-27. 
27. Péley G, Farkas E, Mátrai Z, Rényi-Vámos F, Kovács T, Köves I The role of surgery 
in the treatment of malignant melanoma. Magy Seb. 2003, 47: 69-77.  
 
QUOTABLE CONGRESS ABSTRACTS 
1. Mátrai Z., Tóth L., Szentirmay Z., Rényi Vámos F., Klepetko W., Vadász P., 
Kenessey I., Kásler M. Sporadical desmoid tumors of the chest. Long term follow-up 
of twenty-eight multimodally treated patients. ECCO 16 – 36th ESMO 
Multidisciplinary Congress, Stockholm, Sweden Eur. J. Cancer 2011, 47: 667 (poster 
presentation)  
2. Mátrai Z., Péter I., Tóth L., Csernák E., Antal I., Sávolt Á., Bartal A., Kásler M. High 
frequency estrogen receptor beta expression in sporadic aggressive fibromatosis. 
Immunohistochemical analysis of 57 cases. The 4th Conference of Phd Students and 
the First Conference of Postdoctoral Researchers in Medicine and Pharmacy, Targu 
Mures, Romania Acta Medicina Maresiensis 2011, 57: 4 (oral presentation) 
3. Mátrai Z. Desmoid tumor associated with a ruptured silicone breast implant. A case 
report. International Oncoplastic Breast Surgery Symposium, Tokyo, Japan. 2010 
Abstact book P25-20 (poster presentation) 
4. Mátrai Z., Tóth L., Rényi-Vámos F., Szentirmay Z., Papp J., Klepetko W., Szenrdıi 
M., Vadász P., Kenessey I., Sávolt Á., Bartal A., Kásler M. Sporadical desmoid 
tumors of the chest. Long term follow-up of twenty-eight multimodally treated 
patients. 4th Scientific Meeting of the Japan-Hungarian Surgical Society, Yokohama, 
Japan. 2010 Abstract book P94 O10-4 (oral presentation) 
5. Mátrai Z., Tóth L., Gulyás G., Szabó É., Szentirmay Z., Papp J., Bartal A., Kásler M. 
Desmoid tumor associated with a ruptured silicone breast implant. The 60th Congress 
of the Hungarian Surgical Society, Siófok, Hungary. Magy. Seb. 2010, 63: 214 (oral 
presentation) 
6. Mátrai Z., Orosz Zs., Papp J., Vadász P., Szendrıi M., Rahóty P., Pápai Zs., Tóth L. 
Long-term results of the surgical and combined treatment of sporadic desmoid tumors 
of the thoracic wall: a multicenter, retrospective trial with 28 patients”, The XXVIII. 
Congress of the Hungarian Society of Oncology, Budapest, Hungary. Magy. Onkol. 
2009, 53: 77. (poster presentation) (awarded 3rd place) 
7. Mátrai Z., Orosz Zs., Oláh E., Papp J., Csekeı A., Vadász P., Szendrıi M., Rahóty 
P., Pápai Zs., Rényi Vámos F., Köves I. Long term follow-up of sporadic desmoid 
tumors of the thorax. A multicentric retrospectiv analysis of 25 patients. 59th 
Congress of the Hungarian Surgical Society, Debrecen, Hungary. Magy. Seb. 2008, 
61: 176 (oral presentation) 
 5 
8. Mátrai Z., Papp J., Peter I., Szendrıi M., Rahóty P., Pápai Zs., Köves I., Oláh E. 
Clinical follow-up of desmoid tumors and the impact of APC gene mutations. ECCO 
14 The European Cancer Conference, Barcelona, Spain Eur. J. Cancer 2007, 5, 404. 
(poster presentation) 
9. Mátrai Z., Papp J., Péter I., Szendrıi M., Rahóty P., Pápai Zs., Sápy Z., Oláh E., 
Köves I. Clinico-pathological follow up of desmoid tumor patients and the impact of 
APC gene mutations. The XXth Congress of Coloproctological Section of the 
Hungarian Surgical Society and Joint Meeting of the European Federation for 
Colorectal Cancer, Debrecen, Hungary. 2007 Abstract book P34 (oral presentation) 
10. Mátrai Z., Papp J., Peter I., Szendrıi M., Rahóty P., Pápai Zs., Oláh E., Köves I. 
Clinical follow-up of desmoid tumors and the impact of APC gene mutations. 19th 
Meeting of Europan Association for Cancer Research EACR, Budapest, Hungary. 
2006 Proceedings of EACR P206 Poster 342 (poster presentation) 
11. Mátrai Z., Papp J., Péter I., Szendrıi M., Rahóty P., Pápai Zs., Oláh E., Köves I. 
Clinico-pathological follow up of desmoid tumor patients and the impact of APC gene 
mutations. 58th Anniversary Congress of the Hungarian Surgical Society, Budapest, 




The World Health Organization defines desmoid tumors as „clonal fibroblastic proliferations 
that arise in the deep soft tissues and are characterized by infiltrative growth and a tendency 
toward local recurrence but an inability to metastasize”. Regarding the biological background 
of the tumor, it is classified between benign fibrous tissue proliferation and fibrosarcoma. 
Desmoids are rarely occurring tumors which account for 0.03% of all neoplasms. The 
estimated annual incidence in the general population is 2–4 per million. The peak incidence of 
the tumor is between 25 and 40 years of age. Two different types have been described: most 
of them belong to the sporadically occuring type (95%) and the rest are associated with 
hereditary cancer syndromes like the autosomal dominant familial adenomatous polyposis 
(FAP, Gardner) syndrome. The sporadic types are more common in women than in men with 
a ratio between 1.8 : 1 and 5 : 1. 
 
1.2. Clinical presentation  
Desmoids develop from musculoaponeurotic structures throughout the body and are classified 
as extra-abdominal, abdominal and intra-abdominal. The clinical manifestation of desmoids is 
non-specific. Little or no pain accompanies extra-abdominal fibromatoses which typically 
arise as firm, poorly circumscribed, deep-seated, furtively grown masses. Tumors are fixed to 
the musculoaponeurotic plane and are usually free in relation to the bone, and joint capsule, 
only rarely adhering to these. Muscular retractions, deformity, limited or lost joint functions 
or even the lifethreatening compression of vital organs may be caused when the tumour 
reaches a large size. When a desmoid is diagnosed, a thorough family history is necessary to 
be taken, examination, genetic counseling and colonoscopy should be performed in order to 
outrule Gardner’s syndrome. 
 
1.3. Clinical behaviour 
The clinical behavior and natural history of desmoids is typically heterogeneous and 
unpredictable and is characterised not only by tumor growth, proliferation and disease 
progression but also by stabilization and spontaneous remission. Most desmoids are however 
slowly growing neoplasms, they aggressively invade surrounding tissues and organs, do not 
metastasize but bear a high propensity (20% to 85% in 10 years) for local recurrence. Despite 
their benign nature, the tendency to recur and the infiltrative growth remain significant 
problems in terms of morbidity and even mortality.  
 
1.4. Etiology 
Some authors considered them as non-neoplastic processes and others described desmoids as 
well-differentiated low grade sarcomas. In fact, the etiology is likely multifactorial and 
includes genetic, endocrine and physical factors as well.  
 
1.5. The neoplastic nature of desmoids  
Multiple studies described the clonal nature of desmoids pointing at malignant capacities that 
place these tumors into the category of fibroblastic malignancies. The understanding of the 
molecular etiology of desmoids is mandatory. A common feature detected is deregulated Wnt 
signaling via β-catenin–dependent activation of latent T-cell factor/lymhpoid enhancer factor 
(Tcf/Lef), a pathway with a critical role for instance in embryogenesis, cell adhesion, 
carcinogenesis, in adult stem cell survival and self-renewal during wound healing. Desmoids 
arising in patients with FAP show loss of adenomatous polyposis coli (APC) tumor 
suppressor function, which leads to high intracellular β-catenin levels and is correlated with 
constitutive activation of Wnt signaling. In sporadic desmoids most tumors contain specific 
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point mutations in the catenin beta 1 (CTNNB1) gene, that stabilize β-catenin and achieve a 
similar result. Several mutations of the APC gene in sporadic desmoids lacking β-catenin 
gene mutations have been reported and approximately 95% of these lead to expression of a 
truncated protein. It has been suggested, therefore, that the higher β-catenin protein levels are 
consequences of the APC gene truncation in the absence of β-catenin mutations. It is 
proposed that APC mutations cause inadequate regulation of β-catenin activation, leading to 
proliferation on a cellular level, and the location of the APC or β-catenin mutation dictates the 
phenotype of desmoid tumor expression.  
 
1.6. The endocrine etiology of desmoids  
A possibility of functional interaction between estrogen receptor (ER) and Wnt/β-catenin 
signaling has recently been reported in human tumor cell lines and in Drosophila, in which 
estrogen signaling appears to potentiate the effects of nuclear β-catenin, though evidence for 
interaction of the ER pathway with the APC/ β-catenin pathway is circumstantial.  
 
1.7. Histology 
The macroscopical appearance of desmoid tumors is firm and rubbery, and characterised by a 
relatively homogenic incisional surface of white and greyish network of bundles resembling 
scar tissue with a relatively poor vascularization. At microscopical presentation a proliferation 
of elongated, slender, spindle-shaped cells of uniform appearance, arranged in fascicles is 
seen, sometimes with perivascular oedema. Immunohistochemistry (IHC) is positive for 
vimentin, alpha smooth muscle actin, muscle actin, and desmin muscle cell markers. Nuclear 
β-catenin immunoreactivity is staining positive in 67%–80% of cases in the reported series. 
The IHC studies on hormone receptor status showing uniform negative for ER-α and 
progesterone receptor, but 7.4% to 100% positive for ER-β.  
 
1.8. Treatment of desmoid tumors  
The optimal therapy for desmoids is difficult to be established due to the heterogeneous 
clinical behavior and anatomical presentation. There is limited or no evidence based medicine 
for these type of tumors. The general recommendations for the efficacious managment of 
desmoids consist of surgical and nonsurgical modalities and require a multidisciplinary 
approach. The treatment should be decided on case-by-case basis by the multidisciplinary soft 
tissue board.  
Close observation is an acceptable strategy for asymptomatic patients with small desmoid 
tumors not infiltrating any nearby structures or for patients of stable disease presenting with 
few, mild symptoms.  
If the preoperative diagnostics finds that a desmoid tumor is technically resectable, aggressive 
surgery is the first line treatment. To date wide excision with 2 to 4 cm resection margins is 
generally recognized as the most effective treatment for desmoids. Complete resection of the 
lesion with negative microscopic surgical margins (R0 resection) is the standard surgical goal, 
however, it is not always possible due to anatomic boundaries. The overall strategy should be 
to attempt complete removal using function-preserving approaches to minimize major 
functional and cosmetic morbidity. Incomplete resection is associated with a higher risk of 
local recurrence. The importance of a negative surgical margin is thus recently debated.  
Radiation therapy (RT) is considered an effective option in the therapy of desmoid tumors, 
that may improve local control. The role of adjuvant RT in achieving local control has not yet 
been clearly defined and is still controversial. Postoperative RT is considered only in patients 
with a large tumor and positive margins as suggested in the National Comprehensive Cancer 
Network (NCCN) guidelines.  
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For patients with positive resection margins, advanced desmoids that are not amenable to 
surgery or RT, various medical treatment options including antihormonal therapies, non-
steroidal anti-inflammatory drugs (NSAIDs), targeted therapies, and traditional cytotoxic 
chemotherapies have been investigated.  
 
1.9. Posttreatment surveillance 
Given the increased potential for recurrence, regular clinical and possible imaging follow-up 
have been strongly recommended after therapy. Consensus-based guidelines from the NCCN 
suggest that a history and physical examination with appropriate imaging (preferably MRI) 
every 3–6 months for 2–3 years and then annually.  
 
AIMS OF THE THESIS 
There is a relative paucity of clinical and patholo-gical data is available on sporadic desmoid 
tumors. As the data found in the English language literature are mostly based on the meta-
analysis of case reports or series, or retrospective studies with low number of cases, a global 
lack of knowledge is recognised regarding risk factors, multidisciplinary treatment modalities, 
prospective and predictive factors and long-term follow-up results.  
Given these facts, the main aims of our investigations were as follows: 
1rst aim. To establish a data base of sporadic desmoid tumors adequate for analytical purposes 
and, to collect clinico-pathological data on long term follow-up in order to find scientific 
answers to the questions of etiology, pathology and clinical behaviour.  
2nd aim. On the basis of a detailed clinico-pathological database the first planned step was to 
confirm the sporadical origin of desmoids by ruling out the FAP associated germ line 
mutation of the APC gene by clinical and genetic investigations.  
3rd aim. To confirm the theory of the etiology of sporadic desmoids, by detecting the β-
catenin mutation status with molecular-genetical probes in a large number of tissue samples, 
quilting as one of the largest single cohort reported in the literature.  
4th aim. To analyse and compare the clinical and pathological data of the very rare thoracic as 
well as the more common abdominal tumors and desmoids located on the extremities.  
a. Radicality of first surgery and its influence on local control. 
b. The analysis of the surgical techniques and the reconstructive methods after wide 
soft tissue resections (e.g. long time results with mesh reconstructions after the 
resection of abdominal desmoids). 
c. The correlation of genotyping results with clinical and immunohistochemical 
features, including time to recurrence and β-catenin protein expression pattern and 
intensity.  
d. To establish possible prospective and predictive factors on the basis of the 
correlation of genotyping and long-time clinical course. 
5th aim. Assessment of the expression of ERs and PR in sporadical desmoid tumors by 
immunohistochemical analysis using anti-ER-α, anti-ER-β and anti-PR antibodies. 
a. The comparison of the clinical tumor status with the adherent ER-β status of 
patients following endocrine treatment. 
 
MATERIALS AND METHODS 
1. The creation of a cohort of sporadic desmoid cases and a data base  
With the approval of the Institutional Ethical Board, a cohort of desmoid cases was collected 
by multicentric way, using the soft tissue tumor database of the National Institute of Oncology 
(NIO), the Semmelweis University Orthopaedic Clinic and the Thoracic Surgical Clinic of 
Koranyi National Institute of Pulmonology. The cases were multidisciplinary treated between 
1982 and 2011. The medical records and tissue samples were collected by personal research 
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of the archives of the institutes. All patients were invited for a face to face consultation and 
clinical investigation. Clinical information including demographic, therapeutic, tumor, and 
clinical outcome variables were retrieved and tabulated for correlative analyses.  
Occasional (28 cases) or regular follow-ups (69 cases) were realized by 97 patients in the NIO 
with the succesful completion of the clinical and anamnestic database. Regular follow-ups 
were performed as recommended in the literature. The tissue samples of all cases were 
officially acquired from all three pathological departments and histologically revised by an 
independent reference pathologists in the NIO. Demographic and clinical data were gathered. 
Therapeutic data acquired consist of the type and number of surgical interventions, surgical 
margins, reconstructive plastic surgical options, perioperative morbidity, mortality, adjuvant 
therapy administered and its efficacy using the RECIST 1.1. criteria. Pathological data consist 
of the pathological tumor size, the circumferential microscopical surgical margin, results of 
IHC assays. The database is continously updated enabling long term follow-up and analytical 
comparison of the data. A limitation of the study was the principally retrospective collection 
of data, the incidental low-quality of a few decade-old pathological tissue samples, and the 
low number of cases preventing a reliable statistical comparison of subsets of patients. 
Although during the nearly 30 years of patient recruiting period, surgical resection and non-
surgical therapies as first choice of treatment have not or only minimally (imatinib) changed, 
a further limitation was proposed by the non-controlled therapies. 
 
2. Confirmation of the sporadical origin of desmoid tumors by ruling out the germ line 
mutation of APC gene. 
All participants were asked for detailed family history, and a three-generation family tree was 
delineated. Medical records for family members who have developed colon polyps and/or 
underwent colon surgery were requested, and took a survey in order to evaluate the presence 
of FAP. Colonoscopy was performed or former medical records were checked for all the 
patients. Thirty-nine individuals included in this study were referred to genetic counseling and 
testing to the Department of Molecular Genetics at the NIO. All investigations have been 
performed in agreement with international guidelines, the study protocols were approved by 
the Institutional Ethical Board. Written informed consent was signed by each patient. DNA 
was extracted from peripheral blood samples of all consenting subjects using the classic 
phenol-chloroform method. The entire coding region and splice junctions of the APC gene 
were amplified by polymerase chain reaction (PCR). Mutation pre-screening was done on the 
resulting PCR amplicons using single-strand conformation polymorphism /heteroduplex 
analysis technique (SSCP/HDA). Bands on gels were visualized by silver staining. Where 
altered mobility of a sample indicated the presence of a variant, the fragment was subjected to 
direct bidirectional DNA sequencing. Completed sequencing reactions were electrophoresed. 
The presence of mutations was confirmed using a different blood sample.  
 
3. Detection of the β-catenin mutation status. 
Only sporadic desmoid tumors were evaluated. As tissue samples were only partly suitable in 
quality for molecular-genetic investigations, an amount of 58 specimens from 51 patients 
were found to be eligible for the β-catenin mutation analysis. The samples from formalin-
fixed, paraffin embedded tissue sections were analysed for CTNNB 1 gene mutation status 
with locked nucleic acid (LNA) probe-based real-time (PCR) followed by melting curve 
analysis. 
 
4. Three groups were formed following the analysis and comparison of clinical and 
pathological data: sporadical desmoid tumors of the chest, abdominal wall tumors and 
fibromatoses originating in the extremities. 
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Dividing the sporadical desmoid cases into 3 different groups seemed a resonable option, 
based on the diversity of the surgical techniques, radicality and methods of tissue 
reconstruction according to the location of the tumors of the available 94 sporadical cases in 
the database. The therapeutic protocol for desmoids was invariable during the investigated 
period. First-line treatment was wide surgical resections. The radicality of the surgery was 
considered to be R0 if the circumferential surgical margins were microscopically negative, R1 
and R2 if microscopic residual tumor and gross residual disease respectively was left behind. 
The largest diameter of the tumor and the status of the surgical margin were defined by the 
pathological befund. All operations were performed under antibiotic prophylaxis with 
amoxicillin or cefazolin (a single intravenous shot of 1000 mg of amoxicillin and 200 mg of 
clavulanic acid or 1000 mg of cefazolin), or continued until the suction drains were removed 
over the implanted mesh graft. According to the applied protocol, patients exposed to the 
potential of major complication (intra-thoracic location or lesion adjacent to joint capsule or 
great vessels) and those with R1 resections received 20 mg of oral tamoxifen daily, otherwise 
close surveillance was implemented. Higher dose of tamoxifen (120 mg daily) and sulindac 
(150 mg/twice daily) were administered to patients with unresectable lesions or R2 resections. 
In cases of recurrence, a daily dose of 20 to 120 mg tamoxifen and 150 to 300 mg sulindac 
were administered. The therapy of high dose tamoxifen in combination with sulindac was 
continued for a maximum of 24 months, followed by maintenance daily doses of 20 mg of 
tamoxifen and 150 mg of sulindac. Patients who received sulindac were under regular 
cardiological control. Radiotherapy was indicated in agressive cases showing rapid 
progression in an adjuvant setting or in irresectable cases showing tumor progression. The 
dose of RT for definitive therapy was 50–60 Gy in 5–7 weeks at 1.8–2 Gy per fraction, with 
wide radiation field margins of at least 5 cm applied in the direction of possible infiltrative 
growth. Doxorubicin based chemotherapy was administered in a single advanced case 
locating in the neck with life-threatening morbidity. Operative morbidity was recorded within 
the first 30 days after surgery or during the same hospitalization. There was no record of 
malignant disease in the histories of the 94 investigated patients. The soft tissue follow-up 
protocol of the participating institutes corresponded with the international recommendations. 
The investigated cases were analyzed for family history, age, gender, previous trauma to the 
site of the tumor, size and site of the tumor, radicality of surgeries, results of IHC assays, 
reconstructive plastic surgeries, perioperative morbidity, number of recurrences, time to 
recurrencies, and adjuvant therapeutic modalities. For all patients, analysis of time to 
recurrence was calculated from the first surgery of primary lesions to the diagnosis of the first 
recurrence. 
 
5. Assessment of the expression of ERs and PRs in sporadical desmoid tumors by 
immunohistochemical assays. 
Histological samples of sporadically occurring primary desmoids acquired from 67 patients 
were eligible for the IHC investigations. Each diagnosis was reviewed and confirmed based 
on the relevant WHO criteria. Normal and neoplastic human breast tissue from the surgical 
pathology laboratory were used as positive control tests. Normal mouse or rabbit sera were 
used instead of the first antibodies in negative control tests. Classification as positive was 
done either according to company guidelines or institutional standard protocols for the 
positive controls: a minimum of 10% of the tumor cells had to be positive for ER-α, ER-β or 
progesteron receptor. Only definite nuclear staining was regarded as positive and cases were 
scored by the percentage of tumor cells staining as 1+ (<10%), 2+ (10-50%), or 3+ (>50%). 
Normal breast tissue served as control for ER-α, and benign fibroadenoma served as positive 
control for ER-β, and were run parallel. The staining on the entire array was performed at the 
clinical IHC facility of NIO on two occasions and each was scored independently. 
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6. Statistical methods 
Categorical data were compared using Fisher’s exact probability test and chi-square test. 
Recurrence free survival analyses were done using the Kaplan—Meier method. Recurrence 
free survival intervals were determined as the time period from initial diagnosis to the time of 
first recurrence. Univariate analysis of potential factors affecting recurrence-free survival 
(gender, age, tumor size, radicality of the first surgery, and impact of the pharmacologic 
treatment) was performed using Cox-regression hazard model. Differences were considered to 
be statistically significant when p < 0.05. Statistica 8.0 (StatSoft, Tulsa, OK) was used to 
perform all of the statistical calculations.  
 
RESULTS 
1. The successful gathering of a cohort of sporadic desmoid cases and creation of a 
database 
A cohort of altogether 97 desmoid cases was collected by the investigator. Fifty-seven cases 
were primarily treated in the NIO, 38 cases at the Semmelweis University Orthopaedic Clinic 
and 2 cases at the Thoracic Surgical Clinic of Koranyi National Institute of Pulmonology. 
Three cases were excluded from the investigation due to confirmed hereditary origin. In all 
the cases the personal attendance of the patient, family and personal anamnesis as well 
physical investigation and completion of the medical records were succesfully achieved. The 
94 sporadic desmoid cases represented 66 female and 28 male patients. The median age of the 
patients was 31 years (range, 9—74 years) and fifty-three female patients (80.3%) were 
premenopausal. Physical, often surgical trauma to the site of the lesion preceeded the 
development of desmoids in 26 patients (28%). Desmoids were located on the region of the 
chest in 28 patients, in the abdominal wall in 28 patients and in the extremities in 38 patients. 
As for the surgical radicality of the primary tumor, 52 cases (55.5%) resulted in R0, 39 cases 
(41.5%) in R1 and 3 cases (3%) in R2 resections. A reconstructive surgical procedure was 
performed in 54 cases (57%). Perioperative morbidity was detected in 19 cases (20%), while 
perioperative mortality didn’t occur. The median pathological diameter of the primary tumors 
was 61 mm (range, 20—250 mm). Adjuvant therapy was commenced for 50 patients (53.2%), 
while 44 patients (46.8%) did not need adjuvant treatment. The non-surgical modalities in the 
adjuvant setting varied greatly. Tamoxifen monotherapy in 20 cases (40%), tamoxifen in 
combination with sulindac in 17 cases (34%) including one patient who received imatinib too. 
Sulindac monotherapy was chosen for 2 patients (4%). Ten patients (20%) received adjuvant 
RT, 8 cases (16%) in combination with tamoxifen, complemented with sulindac in one case, 
and with chemotherapy in another one. Tamoxifen was administered to 48 out of the 50 
adjuvant cases (96%). Follow-up was completed in all investigated patients and ranged from 8 
to 336 months, with a median of 98 months. During the follow-up period a total of 122 local 
recurrence happened. Taking the 3 cases with R2 resection into consideration, among the 91 
cases with R0 or R1 resection 38 cases (41.8%) were recurrence free and local recurrence 
occured in 53 cases (58.2%). Among the 91 cases with R0 or R1 resection 38 cases (41.8%) 
were recurrence free and local recurrence occured in 53 cases (58.2%). Twenty-two cases 
developed one, 13 cases two and 18 cases 3 or more local recurrences. Surgical resection due 
to a recurrent tumor was performed 105 times. The radicality (R0 vs. R1 or R2) of the re-
resections decreased significantly (P=0.0016) from the 2nd recurrence on.  
 
2. Confirmation of the sporadical origin by ruling out germ line mutations of the APC 
gene by clinical and genetic investigations. 
Three patients were found to carry a deleterious APC mutation in the screened section of the 
gene and were subsequently excluded from the further investigations. All of these patients 
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were diagnosed with both desmoid tumors and prominent colorectal polyposis. The three 
patients with hereditary desmoids were excluded from the further investigations. At the last 
follow-up only one of them was alive. The remaining 94 cases were confirmed as sporadic 
desmoids. None of them had a positive family history, nor developed polyposis contolled by 
colonoscopy during the follow-up period. In conformity with the literature, our investigation 
approved the reliability and cost effectivity of genetic testing the APC gene.  
 
3. The detection of the β-catenin mutation status. 
3.1. CTNNB1 Mutations Are Highly Prevalent in Sporadic Desmoid Tumors 
Fifty-eight tissue samples from 51 patients were eligible for evaluating the prevalence of 
CTNNB1 mutations. The database provided appropriate clinical information in relation to the 
35 female (68.6%) and 16 male (31.4%) patients. Median age was 33 years and ranged from 8 
to 66 years. The following sites were involved: chest in 13 cases (25.5%), abdominal wall in 
17 cases (33.3%) and extremities in cases 21 (41.2%). Tumors presented with variable size 
ranging from 20 to 240 mm (median, 83 mm). A mutation was identified in 30 (58.8%) of the 
51 primary tumors. The CTNNB1 exon 3 mutation profile in tissue samples taken from 
recurrent desmoids were 100% identical with the mutation profile of the primary tumor of the 
same patients. Female patients were more likely than male patients (60% versus 50%) to have 
a mutation but the difference didn’t prove to be significant (P= 0.387). Next the CTNNB1 
mutational spectra was determined. Interestingly, only 3 different point mutations in 2 
different codons (41 and 45) could be identified in all mutated samples (n=30 of 51 total): 
ACC to GCC in codon 41 (41A), resulting in the replacement of threonine by alanine, was 
identified in 15 samples (50%); TCT to TTT in codon 45 (45F), resulting in the replacement 
of serine by phenylalanine, was identified in 12 cases (40%); TCT to CCT in codon 45 (45P), 
resulting in the replacement of serine with proline, was identified in1 sample (3.3%) and a 
deletion was identified in 2 cases (6.7%). Upon analyzing the incidence of the specific 
CTNNB1 gene mutations and their correlation to  patient and tumor variables, a higher 
incidence of the 41A and 45F mutation was identified in females versus males (75% versus 
25%, and 73.3% versus 26.7% P=0.922). In terms of tumor site, lesions involving the 
extremities showed a significantly higher incidence of the 45F mutation (58,3%, P=0.018) 
and tumors originating in the abdominal wall showed a significantly higher incidence for 41A 
mutations (60%, P=0.037) versus all other sites. 
 
3.2. CTNNB1 45F Mutations Significantly Correlate with Increased Desmoid 
Recurrence 
The investigator assessed the correlation of the mutation of any specific CTNNB1 gene with 
clinical outcome. The different CTNNB1 gene mutational cohorts were found to present with 
different recurrence-free survival values, which was significantly inferior for patients with the 
45F genotype (P=0.008) (Cox-regression). Only one sample was found to harbor a 45P 
CTNNB1 gene mutation, and so this tumor was excluded from analysis. Younger age (<30) at 
diagnosis as an increased propensity for local recurrence was further identified by univariate 
analysis (P=0.002). Other parameters just as gender, tumor sites (chest vs. abdominal wall vs. 
extremities) and tumor size did not show significant difference. Multivariate analysis was not 
performed due to the low number of cases. The 45F CTNNB1 gene mutation-harboring 
tumors demonstrated significant difference to WT tumors in comparison with local recurrence 
rate using the log-rank analysis (P=0.009).   
   
 
4. The analysis and comparison of the clinical and pathological data of the sporadical 
desmoids in the three subgroups. 
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4.1. Sporadical desmoid tumors of the chest 
There were 19 female and 9 male patients with a median age of 35 years (range, 11—74 
years). As many as 64% of the tumors originated in the shoulder girdle. Upon the pathological 
examination of the primary specimens, an R0 excision was achieved in only 50% of the 
patients. Of the 27 macroscopically wide surgical excisions, 10 cases (37%) were full-
thickness and 17 cases were (63%) partial-thickness chest wall resections. Partial or complete 
scapula and clavicle resections waere performed in six and four cases respectively. The 
disease of 3 patients necessiated compartment resection. The median pathological diameter of 
the resected tumors was 50 mm (range, 20—210 mm). Nine patients had their chest walls 
stabilized by synthetic meshes and no detectable implant complications occurred. Pleural 
involvement indicated wedge resection of the lung in 3 patients. Soft tissue coverage was 
achieved with transposed muscles in six patients. The rate of complications was 25%. No 
operative deaths occurred. In the subsequent follow-ups, first recurrences were noted in 17 
(63%) of the 27 resectable (in both R0 and R1) patients while 10 patients (37%) remained 
recurrence free. The median time to first recurrences was 30 months (range, 10—120 
months). Altogether, 35 surgeries were performed on recurrences. One patient died of stroke 
before the end of the follow-up, another patient was in a weak general condition due to an 
extensive desmoid in the shoulder girdle, and superior vena cava syndrome was diagnosed in 
yet another case. One patient needed neurosurgical intervention and stabilization of the spinal. 
The median duration of anti-estrogen therapy in 18 patients was 68 months (range, 10—171 
months) and the median length of tamoxifen and sulindac combinaton therapy in 12 patients 
was 48 months (range, 10—118 months). ER-β positivity was observed in 50% of the 
samples. RT was applied in 2 patients with recurrent tumors. Both lesions were observed to 
recur and progress 9 and 14 months after treatment, respectively. A total of 16 patients (57%) 
were found to be recurrence free, whereas residual or recurrent tumors were detected in 12 
patients at the time of their last follow-up examination. Statistical analyses of the categorical 
data such as gender, age, tumor size, ER status, and sulindac treatment using Fisher’s exact 
probability test and the chi-square test established that these factors did not correlate with 
surgical radicality. Since tamoxifen was not an independent factor, it could not be used in the 
multivariate analysis. However, local recurrence rate was significantly affected by the surgical 
radicality of the primary tumor (P=0.00065) and sulindac treatment (P=0.029) in the 
univariate analysis by log-rank statistics. Factors that were not significant included gender, 
age, tumor size, and ER positivity. The significant difference on the factors affected by the 
recurrence-free survival group was demonstrated by Kaplan—Meier curves. The multivariate 
Cox regression model confirmed, that the local recurrence rate was only significantly 
affected by the surgical radicality of the primary tumor (P=0.001).  
 
4.2. Sporadical desmoid tumors of the abdominal wall. 
Twenty-three female and 5 male patients belonged to this subgroup with a median age of 29 
(range, 19—59 years). Antedescent surgical or physical trauma to the site of the tumor was 
identified in 7 patients (25%). Primary tumors were located in the anterior abdominal wall in 
100 %, including the inguinal region in 4 cases. Pathological results of the primary specimens 
showed that an R0 excision was achieved in 18 cases (64%). Of the 28 macroscopically wide 
surgical excisions, 18 cases (64%) were full-thickness and 10 cases were (36%) partial-
thickness abdominal wall resections. The median pathological diameter of the resected tumors 
was 63 mm (range, 20—180 mm). Synthetic meshes were utilised for the stabilisation of the 
abdominal wall in all the 28 cases. The applied antibiotic prophylaxis ensured the lack of 
detectable implant complications, only a superficial wound infection localised to the subcutis 
was detected. Soft tissue coverage with transposed musculocutaneous flaps was not necessary 
to perform. No perioperative deaths occurred. The rate of complications was 10.5%. First 
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recurrences were recorded in 10 (35.7%) of the 28 resectable (R0 and R1) patients during the 
subsequent follow-ups. The follow-ups were completed in all of the investigated patients. 
Eighteen patients (64%) were found to be recurrence free. The median time to first 
recurrences was 26 months (range, 6—110 months). Altogether, 17 surgical interventions 
were performed due to recurrences. All patients were alive and tumor free at the last follow-
up. Abdominal wall hernias developed in 3 patients, and in one case mesh bulging was 
confirmed. The median duration of tamoxifen therapy in 11 patients was 25 months (range, 
8—36 months). Four patients received tamoxifen and sulindac combination therapy for the 
median length 20 months (range, 8—25 months). ER-β positivity was observed in 13 cases 
(46.4%) by IHC analysis. All the patients were found to be recurrence free at the time of last 
checkup. Statistical analyses of the categorical data (gender, age, tumor size, ER status) using 
Fisher’s exact probability test and the chi-square test determined that these categories did not 
correlate with surgical radicality. Because of the low number of sulindac use, the cases using 
tamoxifen and sulindac were summed up. The significance of tamoxifen and sulindac 
(p=7.96*10-4) is explained by the adjustment for R1-resected cases and for recurrent tumors, 
corresponding to our adjuvant protocol. As a result, tamoxifen was not an independent factor 
and, it could not be used in the multivariate analysis. In the univariate analysis by Cox-
regression model, the local recurrence rate was significantly affected by the surgical radicality 
of the primary tumor (P=0.006). Factors that were not significant included gender, age, tumor 
size, and ER positivity. The significant difference on the factor affected by the recurrence-free 
survival group was demonstrated by Kaplan—Meier curves.  
 
4.3. Sporadical desmoid tumors of the extremities. 
The subgroup included 24 female and 14 male patients with a median age of 30 years (range, 
9—59 years). Eleven tumors (29%) were located in the upper extremity, while 27 (71%) 
tumors in the lower extremities. Regarding the pathological results of the primary specimens, 
an R0 excision was achieved in only 19 cases (50%). Macroscopically wide surgical resection 
was peformed in 32 cases (84%) whereas 4 patients (10.5%) underwent compartment 
resection of the buttock resection, adductor compartment, quadriceps and the entire 
brachioradialis muscle. The tumor of one patient originated in the popliteal fossa, thus the 
popliteal arteria had to be grafted. Although en block resection with additional bone resection 
was performed in 1 case, amputations were not performed. The median pathological diameter 
of the resected tumors was 70 mm (range, 25—250 mm). Soft tissue reconstruction was 
performed with transposed myocutaneous flaps in 6 patients (15%), and additional 4 patients 
needed full- or partial thickness skin graft coverage. No operative deaths occurred. The rate of 
peroperative complications was 23.7%. First recurrences were noted in 28 (77%) of the 36 
radically resectable patients. The median time to first recurrences was 32 months (range, 6—
108 months). Ten patients (26.3%) proved to be recurrence free. Altogether 52 surgeries were 
carried out on recurrences and the follow-ups were completed in all of the investigated 
patients. At the last follow-up all the patients were alive. Twenty-seven patients (71%) were 
disease free, and 4 patients had stable disease, while 7 patients had recurent tumors with slow 
progression. Five patients complained about limitation of joint motion, 4 patients experienced 
neurological symptoms like loss of motoric functions, and 7 patients suffered from 
hypesthesia of the affected region or the distal part of the extremity was experienced. The 
median duration of anti-estrogen therapy in 19 patients was 43.2 months (range, 11—78 
months). The median length of tamoxifen and sulindac combination therapy in 4 patients was 
32 months (range, 9—68 months). ER-β positivity was observed in 12 cases (42.8%). RT was 
administered for 7 patients (18.2%). Five of them were observed to be tumor free while 
recurrence was found in 2 cases with a median of 21 months followng treatment. A total of 27 
patients (71%) were found to be recurrence free, whereas residual or recurrent tumors were 
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detected in 11 patients (29%) at the time of their last checkup. As many as 36.3% of the 
recurrences exhibited stable disease according to RECIST 1.1 criteria during the last 6 months 
of follow-up. However 63.7% of the tumors were characterized by a slow progression despite 
the ongoing multimodal therapy. Categorical data such as gender, age, tumor size, ER status 
did not correlate with surgical radicality determined by Fisher’s exact probability test and the 
chi-square test. Because of the low number of cases treated with sulindac statistical analysis 
was unable to perform. The significance of tamoxifen (P=0.007) and RT (P=0.001) is 
explained by the adjustment for R1 or R2 resected cases, corresponding to our adjuvant 
protocol. Neither of these can be considered as an independent factor and thus, could not be 
used in the multivariate analysis. In the univariate analysis by Cox-regression model, the local 
recurrence rate was significantly affected by the surgical radicality of the primary tumor 
(P=0.013). Factors that were not significant included gender, age, tumor size and ER 
positivity. The significant difference on the factor affected by the recurrence-free survival 
group was demonstrated by Kaplan—Meier curves.  
 
4.4 . Comparisons of the clinical results among the three cohorts of different tumor 
locations. 
Significant differences were not detected among the three cohorts in terms of surgical 
radicality of the primary tumor (R0 versus R1 and R2) (P=0.281), gender (P=0.236), age 
(P=0.201), ER-β status (P=0.122) and tumor size (P=0.435).   
The recurrence-free survival showed a decreasing trend among tumor locations as follows: 
abdominal, chest and extremities. Significance was confirmed using log-rank analysis 
between tumor locations ’abdominal’and ’extremity’ (P=0.0061), while no significance was 
found between ’abdominal’ versus ’chest’ (P=0.086) and ’chest’ versus ’extremities’ 
(P=0.253).  
 
5. Assessment of the expression of ERs and PRs in sporadical desmoid tumors by 
immunohistochemical assays. 
The assessment included the tissue samples of 67 sporadical desmoid patients: 51 female 
(76.1%) and 16 (23.9%) male patients with a median age of 32 years (range 9-65 years). The 
tumor was located in the chest in 19 patients (28.35%), abdominally in 20 patients (29.85%) 
and in the extremities in 28 patients (41.8%). Stains for ER-α and PR were uniformly 
negative, whereas 36 cases (53.7%) displayed expression of ER-β: 3+ expression in 31 cases 
(86.1%), 2+ expression in 4 cases (11.1%) and 1+ expression in one case (2.8%). There was 
no significant correlation between the ER-β status and gender (P=0.732), age (P=0.281) or 
location (P=0.289) and size (P=0.924) of the tumor. R0 resection was achieved in 38 cases 
(56.7%) only. The median pathological tumor diameter of the investigated cases was 80 mm 
(range 25-210 mm). Thirty-two pateints (47.7%) in the IHC screened group received adjuvant 
tamoxifen treatment. Fourteen of the 32 patients (43.75%) treated with tamoxifen and 
subjected to clinical assessment had ER-β positive tumors. At a median follow-up time of 110 
months (range, 5 to 336) 43 cases (64.2%) had local recurrences, and no difference between 




1. Successful creation of a cohort of sporadic desmoid cases and a database 
The relatively large number of patients with sporadic primary desmoids, the constant 
therapeutic modalities, and the long term clinical follow-up (median 98 months) together 
proved to be eligible for molecular-genetic and IHC investigations and scientific analysis of 
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the data. The database was registered to the national and the European databases of rare 
diseases and soft tissue tumors, to support additional scientific research of sporadic desmoids.  
 
2. Confirmation of the sporadical origin of the desmoid tumors. 
Testing for APC germline mutations in FAP families has become an efficient tool for 
predictive testing of subjects at possible risk and is now commercially available and has led to 
changes in management guidelines, particularly for those whose tests indicate they are not 
mutation carriers. If the germline mutation causing FAP is detected in a given family, carriers 
are selected who need to undergo surveillance by regular endoscopies. Presymptomatic 
genetic diagnosis of supposed FAP patients has been feasible with linkage and direct 
detection of APC mutations. Beside the desmoids in all 3 germline mutated cases other 
manifestations of FAP syndrome appeared such as multiple colon polyps or polyposis. After 
the exclusion of the FAP-associated cases, the remaining 94 patients with negative clinical 
and genetic tests and family anamnesis did not show any signs of FAP during the median 
follow-up time of 98 months. Colonoscopy was performed in every 5 years in the investigated 
population. Sporadically, polypectomies were performed, but multiple polyps or polyposis 
were not detected. On the bases of the above detailed experiences and results the author 
agrees that genetic testing together with accurate family anamnesis, physical investigation and 
colonoscopy is a reliable and non-invasive method to confirm FAP even without positive 
family anamnesis. It is imperative that FAP families be referred for genetic counselling, 
genetic testing, early diagnosis, and clinical management to centres that are aware of the 
complexity of both surgical intervention and possible implications of molecular findings for 
individual patients. 
 
3. The detection of the β-catenin mutation status. 
The present study identified CTNNB1 gene mutations in 58.8% of the investigated 51 cases. 
This finding further confirms the results of a recently published series, strongly suggesting 
that CTNNB1 mutations are highly prevalent in sporadic desmoids. In conformity with other 
publications we have also observed that desmoid CTNNB1 mutational spectra are rather 
limited. Interestingly, only three specific mutations are noted: 2 involving codon 45 and 1 
involving codon 41, with all mutations clustered at Threonine 41 (41A) and Serine 45 (45F 
and 45P) in all topographies, suggesting that these residues have crucial functions in the β-
catenin/Wnt signaling pathway. In our study we identified that risk of recurrence in desmoids 
is significantly associated with the specific CTNNB1 mutation of 45F (P=0.022). A larger 
than threefold increased risk of recurrence is found in tumors with this mutation, proposed to 
begin to be manifest at a significantly earlier time point in the desmoid tumor-host encounter. 
Our findings suggest that the biological consequences of the 3 different CTNNB1 mutations 
in exon 3 are not equivalent. Our study supports a role for 45F mutation as a prognostic factor 
strongly associated with recurrence. Due to the high propensity for recurrence of desmoids, 
the use of nonsurgical approaches as adjuvant strategies may be useful in preventing 
recurrence, especially in recurrence-prone cases such as the 45F mutated lesions. The causal 
relationship between the 45F mutation, β-catenin expression, and desmoid recurrence are still 
to be confirmed in further investigations. Our study suggests that genotyping of CTNNB1 
exon 3 may provide information regarding risk of recurrence and personalised adjuvant 
therapies and as a diagnostic test is could be useful in situations such as insufficient core 
needle biopsies or differentiating a post-surgical scar from desmoid recurrence. Prospective 
trials are needed to test such possibilities.  
 
4. Comparisons of the clinical results among the three cohorts of different tumor 
locations 
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According to our results we can conclude that the surgical radicality of the primary tumor 
served as a significant prognostic factor on local control rate. Another important conclusion is 
that the available surgical radicality significantly declines following the second local 
recurrence. Possible reasons for the phenomenon are proposed to be local anatomy, the 
surrounding postoperative scarry tissues and employed radiotherapy.  
Among the three cohorts of different tumor locations, recurrence-free survival showed a 
decreasing trend as follows: ’abdominal’, ’chest’ and ’extremities’, with a significantly better 
local control in ’abdominal’ versus ’extremities’group. Significant difference was not 
detectable among the three cohorts in terms of the surgical radicality of the primary tumor, so 
the aforamentioned can be explained by the significant occurrence of 45F and 41A CTNNB1 
mutations in the groups of ’extremity’ and ’abdominal’.  
 
5. Assessment of the expression of ERs and PRs in sporadical desmoid tumors. 
In general, it has been suggested that desmoids respond to the manipulation of ER signalling. 
ERs are members of the steroid/thyroid/retinoid hormone receptor superfamily of nuclear 
receptors, binding estrogen with high affinity. Binding to its ligand causes a change in 
receptor conformation that results in dimerisation and binding to specific promoter sequences 
of the DNA. The activated receptor/DNA complex then recruits other cofactors from the 
nucleus, which results in transcription of a protein, causing a change in cell function. Two 
main isoforms of the human ERs (ER-α and ER-β) have been identified. Recently IHC studies 
have found uniform ER-α negativity but high rate of expression of ER-β. In the present IHC 
study of 67 primary desmoids, 36 patients (53.7%) were found positive for ER-β. At a median 
follow-up time of 110 months no statistical difference between the ER-β positive and ER-β 
negative patients treated with tamoxifen were detected. 
 
NEW STATEMENTS 
I. The multicentric creation of a cohort of primary sporadic desmoid tumors was 
succesfully carried out, and proved to be one of the ten largest in the English 
language literature, and the largest in Hungary and suitable for clinico-pathological 
investigations and to join international databases. 
II. Genetic testing of the APC gene is a reliable investigation together with family 
tree analysis and clinical investigations, and so sporadic cases were succesfully 
separated and followed-up; mutation of the CTNNB1 gene was detectable with 
high prevalence in sporadic desmoid tumors; mutation of the 45F gene is 
characteristic for higher recurrence rate, and serving as prognostic factor, the 
optimal choice of individualized adjuvant therapies is enabled.  
III. The cohort of sporadic desmoids of the chest is the second largest of its kind 
reported in the literature. Surgical radicality of the primary tumor was confirmed 
to significantly (P=0.001) determine the recurrence rate. 
IV. The cohort of the abdominal wall sporadic desmoids revealed that surgical 
radicality of the primary tumor as significant prognostic factor (P=0.006) is crucial 
for the disease-free survival. 
V. The recurrence rate in sporadic desmoids of the extremities was confirmed to be 
significantly (P=0.013) determined by the surgical radicality of the primary tumor 
as well.  
VI. Significant difference was not detectable among the three cohorts in terms of the 
surgical radicality of the primary tumor, but significance (P=0.0061) was 
confirmed between tumor locations ’abdominal’and ’extremity’ in terms of the 
recurrence-free survival, which can be explained by the significant  occurrence of 
45F (P=0.018) and 41A (P=0.037) CTNNB1 mutations in the two groups.   
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VII. The achieved surgical radicality of the re-resections is decreasing significantly 
(P=0.0016) from the 2nd recurrence, which must be taken into consideration by the 
management of the recurrences. 
VIII. Although a former universal statement existed that sporadic desmoid tumors are 
ER negative, our investigations confirmed a high rate of ER-β positivity.        
 
ACKNOWLEDGEMENT 
First of all I wish to thank my promoter, Professor Dr. Miklós Kásler, Ph.D., D.Sc., Dr.h.c. for 
his continuous support and encouragement throughout my Ph.D. studies. Furthermore, I wish 
to thank for his valuable inspiration and for introducing me to the oncological world. Besides, 
I would like to thank him for providing me with the professional environment and facilities of 
the National Institute of Oncology to complete my thesis.  
I greatly acknowledge to Professor Dr. Zoltán Szentirmay, Ph.D. and Erzsébet Csernák, M.Sc. 
for the molecular-genetic investigations of β-catenine, and all the collagues from the 
Department of Surgical and Molecular Oncopathology who supported my research. 
I wish to express my sincere gratitude to Dr. Ilona Péter, Ph.D for the immunohistochemical 
analysis of estrogen receptors. 
I am graeteful to Professor Dr. Edit Oláh Ph.D, D.Sc. academician and Dr. János Papp, Ph.D. 
for performing the genetic testing af APC gene.   
I thank Dr. István Kenessey, Ph.D. for the egregiuos help in the statistical analysis. 
I would like to show my great appreciation to Professor Dr. Miklós Szendrıi, Ph.D., D.Sc. 
and  Professor Dr. Pál Vadász, Ph.D. for their assistance in the creation of the database. 
I thank Professor Dr. László Tóth, Ph.D. and Dr. István Köves, Ph.D. for their support during 
my studies. 
I wish to thank Dr. Rényi Vámos Ferenc, Ph.D. for the help by professional analysis of chest 
desmoids. 
I wish to thank Dr. Emil Farkas, Dr. Ákos Sávolt and all my co-workers, colleagues and staff 
members in the National Institute of Oncology for assisting my studies and research activities 
and for creating a supportive and pleasant working enviroment. 
Finally, an honorable mention goes to my wife, parents, family and friends for 
their understanding and support on me in completing this thesis. 
   
 
